• Users Online: 842
  • Print this page
  • Email this page
Year : 2021  |  Volume : 12  |  Issue : 7  |  Page : 4-11

Recommendations for COVID vaccination for dermatological patients on immunosuppressive/immunomodulatory therapy (IADVL Academy)

1 Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
2 Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India
3 Department of Dermatology and STD, University College of Medical Sciences and GTB Hospital, Delhi, India

Correspondence Address:
Dr. Deepika Pandhi
Chairperson, IADVL Academy, Director Professor, Department of Dermatology and STD, Dilshad Garden, Delhi - 110 095
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/idoj.idoj_412_21

Rights and Permissions

Significant proportion of patients with dermatological disorders are on immunosuppressive or immunomodulatory therapy predisposing them to risk of acquisition of COVID-19 infection. However, the efficacy of COVID-19 vaccination among these patients is a matter of concern due to lack of adequate evidence for their protective effect owing to the drug induced immunosuppressed state. Hence, we from the IADVL academy have framed the recommendations to be followed for COVID-19 vaccination among dermatological patients on immunosuppressive therapy based on available related literature.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal